ENTITY
Innovent Biologics Inc

Innovent Biologics Inc (1801 HK)

357
Analysis
Health CareChina
Innovent Biologics, Inc. operates as a biopharmaceutical company. The Company develops, manufactures, and distributes monoclonal antibody drug candidates for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and other diseases. Innovent Biologics serves customers in China.
more
Refresh
bullishAlphamab Co Ltd
28 Nov 2019 16:23

Alphamab Oncology IPO Initiation: Clear Diagnosis

Alphamab Co Ltd (1728643D CH) is a pre-revenue biotech company with a focus on research and development, manufacturing and commercialisation of...

Logo
473 Views
Share
30 Oct 2019 16:12

SinoMab (中国抗体) IPO - A Hard Sell

SinoMab is a Hong Kong-based biotech company with a focus on mAb-based biologics for the treatment of immunological diseases, launched its book...

Logo
526 Views
Share
09 Oct 2019 09:45

Innovent Biologics - Promising Phase I Results for Lung Cancer

In the recent 2019 World Conference on Lung Cancer held in Spain, Innovent Biologics reported preliminary results from a Phase I clinical trial on...

Logo
425 Views
Share
03 Oct 2019 18:57

Innovent Biologics Placement - Positive Newsflow but Past Deal Performance Weighs

Innovent Biologics is raising USD 314 million to fund its clinical trial in a top-up placement. We have covered the company's listing and the...

Logo
503 Views
Share
18 Sep 2019 15:37

Shanghai Henlius (复宏汉霖) IPO: Take-Aways from Peer PD-1 Sales in China

We have gathered the sales data for PD-1 products from four players in China for the first half of 2019. As its anti-PD-1 monoclonal antibody,...

Logo
511 Views
Share
x